EPAS1
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Renal cell carcinoma [ICD-11: 2C90]
In total 1 item(s) under this disease |
Experiment 1 Reporting the m6A-centered Disease Response
|
[] |
Response Summary |
MTHFD2 plays a critical role in controlling global N6-methyladenosine (m6A) methylation levels, including the m6A methylation of Endothelial PAS domain-containing protein 1 (HIF-2Alpha/EPAS1) mRNA, which results in enhanced translation of HIF-2-alpha. MTHFD2 links RNA methylation status to the metabolic state of tumor cells in Renal cell carcinoma.
|
Responsed Disease |
Renal cell carcinoma [ICD-11: 2C90]
|
Pathway Response |
Glycolysis / Gluconeogenesis |
hsa00010
|
Cell Process |
Aerobic glycolysis
|
In-vitro Model |
() |
() |
() |
In-vivo Model |
Xenograft tumors were generated by injection (5.0 × 106 cells/injection) of shMTHFD2 786-O and CAKI-1 lines and their respective shControl cell lines (n = 6 per line, sample size calculated for 80% power to detect a twofold difference with 95% confidence) subcutaneously into 6-week-old male Nu/J mice.
|
|
|
|
|
|